Biological considerations in the development of a human immunodeficiency virus vaccine

Journal of Infectious Diseases

Volumn 182, Issue 2, 2000, Pages 579-589

  Nathanson, N ^a   Mathieson, B J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MUCOSAL IMMUNITY; PRIORITY JOURNAL; REVIEW; SUPERINFECTION;

AIDS VACCINES; CROSS REACTIONS; DRUG DESIGN; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; TECHNOLOGY, PHARMACEUTICAL; VIREMIA;

EID: 0033840552     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315707     Document Type: Review

References (101)

1. HIV vaccines: Where are we going?
2. Progress in the development of an HIV-1 vaccine
3. Re-emergence of HIV after stopping therapy
4. The AIDS epidemic: Considerations for the 21st century
5. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
6. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial
7. Prevention of perinatal acquisition of hepatitis B virus carnage using vaccine: Preliminary report of a randomized, double-blind placebo-controlled and comparative trial
8. Genetic and immunologic characterization of viruses infecting MN-rgp 120-vaccinated volunteers
9. Advancing AIDSVAX to phase 3: Safety, immunogenicity, and plans for phase 3
10. Immunization with envelope sub-unit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
11. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
12. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp 120 subunit vaccines
13. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines
14. Identification of highly attenuated mutants of simian immunodeficiency virus
15. Protective immunity induced by live attenuated simian immunodeficiency virus
16. Live attenuated SIV: A model of a vaccine for AIDS
17. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation
18. Macaques infected with live attenuated SIV(mac) are protected against superinfection via the rectal mucosa
19. Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces post-challenge virus load in vaccinated rhesus macaques
20. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS
21. Importance of the intracytoplasmic domain of the simian immunodeficiency virus (SIV) envelope glycoprotein for pathogenesis
22. Nucleocapsid protein zinc-finger mutants of simian immunodeficiency virus strain Mne produce virions that are replication defective in vitro and in vivo
23. Potent and stable attenuation of live HIV-1 by gain of a proteolysis-resistant inhibitor of NF-κB (IκB-αS32/36A) and the implications for vaccine development
24. Persistent infection of rhesus macaques by the rev-independent Nef simian immunodeficiency virus SI-V(mac) 239: Replication kinetics and genomic stability
25. Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV
26. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus
27. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus
28. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus
29. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine
30. Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa
31. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
32. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
33. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
34. Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus
35. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1: A report from the Sydney Blood Bank Cohort
36. Identification of a new recipient in the Sydney Blood Bank Cohort: A long-term HIV type 1-infected seroin-determinate individual
37. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients
38. AIDS: Time to turn to basic science
39. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable non-progressing HIV type 1 infection
40. Long-term survival after infection with human immunodeficiency virus type 1 (HIV-1) among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1995
41. Characterization of subtype A HIV-1 from Africa by full genome sequencing
42. Documentation of HIV-1 superinfection and acceleration of disease progression
43. Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1
44. Genetic variation, recombination, and disease in chimpanzees infected with HIV-1 JC499
45. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1
46. Superinfection of chimpanzees with HIV-1 strains representing the same or different subtypes
47. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
48. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
49. HIV-2 and T cell recognition
50. Effects of rapid mass immunization of a population with live oral poliovirus vaccine under conditions of massive enteric infection with other viruses
51. Persistence of immunity following administration of formalin-treated poliovirus vaccine
52. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity
53. +) T lymphocytes from macaques immunized with live attenuated SIV
54. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: Compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates
55. Protection against establishment of retroviral persistence by vaccination with a live attenuated virus
56. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Arkara
57. Protection against mucosal SIV(sm) challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope
58. Potent, protective anti-HIV immune response generated by bimodal HIV envelope DNA plus protein vaccination
59. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIV(mac) 239
60. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus
61. Env-independent protection in duced by live, attenuated simian immunodeficiency virus vaccines
62. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques
63. +) T cell depletion in simian immunodeficiency virus-infected macaques
64. + lymphocytes
65. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. 4. Final report of results based on clinical diagnoses
66. Experimental poliomyelitis following intramuscular virus injection. III. The effect of passive antibody on paralysis and viremia
67. Passive immune globulin therapy in SIV/macaque model: Early intervention can alter disease profile
68. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection
69. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
70. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
71. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
72. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
73. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not p'edicted by genetic subtype. The WHO Network for HIV Isolation and Characterization
74. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus
75. A role for carbohydrates in immune evasion in AIDS
76. HIV entry and its inhibition
77. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
78. Immunotyping of human immunodeficiency virus type 1 (HIV): An approach to immunologic classification of HIV
79. Multivariate analysis of human immunodeficiency virus type 1 neutralization data
80. Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais
81. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians
82. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development
83. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
84. Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection
85. + cytotoxic T lymphocyte responses in early HIV type 1 clade B infection
86. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus
87. +) T cells
88. Epidemiologic aspects of poliomyelitis eradication
89. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1
90. Late seroconversion in HIV 'resistant' Nairobi prostitutes is associated with a preceding decrease in HIV exposure
91. +) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12
92. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
93. + T cell responses associated with control of viremia
94. + T cells in individuals receiving highly active antiretroviral therapy (HAART)
95. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
96. + T-cell responses
97. The role of nonhuman primates in the development of an AIDS vaccine
98. Towards an AIDS vaccine: The role of primate models
99. Towards an AIDS vaccine: The role of non-human primates